CL2024002379A1 - Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso - Google Patents

Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso

Info

Publication number
CL2024002379A1
CL2024002379A1 CL2024002379A CL2024002379A CL2024002379A1 CL 2024002379 A1 CL2024002379 A1 CL 2024002379A1 CL 2024002379 A CL2024002379 A CL 2024002379A CL 2024002379 A CL2024002379 A CL 2024002379A CL 2024002379 A1 CL2024002379 A1 CL 2024002379A1
Authority
CL
Chile
Prior art keywords
diphenyldiazole
pharmaceutical composition
derivatives methods
methods
derivatives
Prior art date
Application number
CL2024002379A
Other languages
English (en)
Spanish (es)
Inventor
Giese Armin
Levin Johannes
Del Vesco Emanuela
Original Assignee
Modag Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modag Gmbh filed Critical Modag Gmbh
Publication of CL2024002379A1 publication Critical patent/CL2024002379A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2024002379A 2022-03-01 2024-08-08 Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso CL2024002379A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22159408 2022-03-01

Publications (1)

Publication Number Publication Date
CL2024002379A1 true CL2024002379A1 (es) 2025-01-24

Family

ID=80623476

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002379A CL2024002379A1 (es) 2022-03-01 2024-08-08 Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso

Country Status (12)

Country Link
US (1) US20250161273A1 (https=)
EP (1) EP4486340A1 (https=)
JP (1) JP2025508912A (https=)
KR (1) KR20240155237A (https=)
CN (1) CN118715010A (https=)
AU (1) AU2023227368A1 (https=)
CA (1) CA3246018A1 (https=)
CL (1) CL2024002379A1 (https=)
IL (1) IL314952A (https=)
MX (1) MX2024009773A (https=)
PE (1) PE20250781A1 (https=)
WO (1) WO2023166045A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025068949A1 (en) 2023-09-26 2025-04-03 Teva Pharmaceutical Industries Ltd. Emrusolmin for use in treating multiple system atrophy
KR20250090047A (ko) * 2023-12-12 2025-06-19 가천대학교 산학협력단 긴 탄소사슬을 포함하는 리파펜틴, 암포테리신 b, 세틸피리디늄, 도미펜, 토코페르솔란을 유효성분으로 포함하는 시누클레인병증 치료용 약제학적 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2687513B1 (en) * 2008-06-09 2020-12-02 Ludwig-Maximilians-Universität München Drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
KR102671166B1 (ko) * 2015-12-14 2024-05-31 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 3,5-디페닐-디아졸 화합물의 수용성 유도체

Also Published As

Publication number Publication date
US20250161273A1 (en) 2025-05-22
WO2023166045A1 (en) 2023-09-07
KR20240155237A (ko) 2024-10-28
EP4486340A1 (en) 2025-01-08
MX2024009773A (es) 2024-08-19
IL314952A (en) 2024-10-01
CA3246018A1 (en) 2023-09-07
AU2023227368A1 (en) 2024-07-18
JP2025508912A (ja) 2025-04-10
CN118715010A (zh) 2024-09-27
PE20250781A1 (es) 2025-03-14

Similar Documents

Publication Publication Date Title
MX2023012725A (es) Compuestos de 2-aminobenzotiazol y metodos de uso de los mismos.
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
NI202000078A (es) Compuestos heteroaril tetracíclicos
MX2019011693A (es) Compuestos que inhiben la proteina mcl-1.
CO2022002842A2 (es) Degradadores bifuncionales de brd9 y sus métodos de uso
CL2024002379A1 (es) Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso
UY38403A (es) Moduladores de la alfa-1 antitripsina
CO2026004964A2 (es) Moduladores de kras
MX2020007947A (es) Inhibidores de erbb/btk.
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
CL2007002166A1 (es) Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
HN2012001162A (es) Triazolopiridinas
UY30759A1 (es) Compuestos quimicos
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
AR047070A1 (es) Derivados de difenilazetidona
BR112023019435A2 (pt) Inibidores de nek7
CO2024015820A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
CO2021009083A2 (es) Compuestos y su uso para el tratamiento de la deficiencia de α1-antitripsina